LOS ANGELES--(BUSINESS WIRE)--Jun 13, 2022-- Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test for Mycobacterium avium paratuberculosis (MAP) – also known as Johne’s disease, that could save the New Zealand dairy industry upwards of $80 million a year in lost production. “The PictArray™ MAP assay would be a positive addition to national control programs to help in the eradication of Johne’s disease from the dairy industry,” says Pictor’s Director of Research and Development, Dr. Natasha Gordon, who will be presenting at a Johne’s disease conference this week in Dublin, Ireland. The PictArray multiplex enzyme-linked immunosorbent assay (ELISA) technology allows multiple biomarkers to be tested in a single well.
Biotech Firm Tackling COVID-19 and M. bovis Announces Successful Development of Rapid, Accurate Johne’s Disease Assay